Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Cycle Regulation

Background:

• The small molecule RITA (reactivation of p53 and induction of tumour cell apoptosis) has been shown to inhibit tumor growth by inducing p53-dependent apoptosis.
• RITA's effects on the DNA damage response pathway, particularly in relation to p53 status, require further elucidation.

Purpose of the Study:

• To investigate the mechanism by which RITA induces DNA damage and apoptosis.
• To determine the role of the ataxia telangiectasia mutated (ATM)/ataxia telangiectasia and Rad3-related (ATR) DNA damage response pathway and checkpoint kinase 1 (CHK-1) in RITA's action.
• To explore the involvement of p53 in regulating the DNA damage response during S-phase.

Main Methods:

• Treatment of cancer cells with RITA.
• Western blot analysis to detect levels of p53, phosphorylated CHK-1 (pCHK-1), and γH2AX.
• Flow cytometry to assess cell cycle progression and DNA damage.
• CHK-1 knockdown experiments.

Main Results:

• RITA activates the canonical ATM/ATR DNA damage response pathway.
• RITA induces p53, pCHK-1, and γH2AX, with increased levels observed during S-phase.
• RITA stalls replication fork elongation, prolongs S-phase, and induces DNA damage in p53-positive cells.
• CHK-1 knockdown did not affect RITA-induced DNA damage or apoptosis but impaired DNA integrity maintenance.

Conclusions:

• RITA activates a p53-dependent DNA damage response pathway.
• A novel p53-dependent S-phase DNA maintenance checkpoint involving CHK-1 exists.
• These findings provide insights into RITA's mechanism of action and potential therapeutic strategies.